8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

May 9, 2014 (May 6, 2014)

Date of Report (Date of Earliest Event Reported)

 

 

ALLERGAN, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   1-10269   95-1622442
(State of Incorporation)   (Commission File Number)  

(IRS Employer

Identification Number)

2525 Dupont Drive

Irvine, California 92612

(Address of Principal Executive Offices) (Zip Code)

(714) 246-4500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.07.    Submission of Matters to a Vote of Security Holders.

Allergan held its Annual Meeting of Stockholders on May 6, 2014 (the “Annual Meeting”) and there were present in person or by proxy 259,206,717 votes, representing approximately 86.65% of the total outstanding eligible votes. At the Annual Meeting, the Company’s stockholders (i) elected nine directors to the Board; (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2014; (iii) approved the compensation of the Company’s named executive officers; (iv) approved the amendment and restatement of the Amended and Restated Certificate of Incorporation; and (v) approved a non-binding stockholder proposal, as more fully described below.

 

     For      Against      Abstain      Broker Non-
Votes
 

Item No. 1: Election of nine directors to serve for a term of office expiring at the 2015 annual meeting of stockholders and until their successors are duly elected and qualified:

 

                 

David E.I. Pyott

   223,086,247      21,045,786      899,279        14,175,405   

Michael R. Gallagher

   163,111,459      81,419,239      500,614        14,175,405   

Deborah Dunsire, M.D.

   232,439,476      12,153,803      438,033        14,175,405   

Trevor M. Jones, Ph.D.

   216,328,825      28,236,839      465,648        14,175,405   

Louis J. Lavigne, Jr.

   232,168,930      12,395,501      466,881        14,175,405   

Peter J. McDonnell, M.D.

   215,837,387      28,727,181      466,744        14,175,405   

Timothy D. Proctor

   229,914,053      14,652,417      464,842        14,175,405   

Russell T. Ray

   230,485,928      14,076,981      468,403        14,175,405   

Henri A. Termeer

 

   232,226,320

 

     12,251,052

 

     553,940

 

      

 

14,175,405

 

  

 

Item No. 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2014

 

   257,654,498      1,086,946      465,273        0   

Item No. 3: Advisory vote to approve the compensation of the Company’s named executive officers

 

   227,667,602      15,798,516      1,565,194        14,175,405   

Item No. 4: Approval of the Amendment and Restatement of our Amended and Restated Certificate of Incorporation

 

   240,369,234

 

     4,134,500

 

     527,578

 

      

 

14,175,405

 

  

 

Item No. 5: Stockholder Proposal

 

                 

Stockholder Proposal # 1 (Right to Act by Written Consent)*

 

   123,331,181

 

     120,819,096

 

     881,035

 

      

 

14,175,405

 

  

 

 

*

Approval of the stockholder proposal requires the affirmative vote of a majority of the shares present at the annual meeting, in person or by proxy, and entitled to vote. Abstentions represent shares present at the annual meeting and entitled to vote; therefore, abstentions have the same effect as votes against the stockholder proposal.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ALLERGAN, INC.  
   Date:   May 9, 2014   By:  

 /s/ Matthew J. Maletta

 
  Name:    Matthew J. Maletta  
  Title:  

Vice President,

Associate General Counsel and Secretary